Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 16 articles:
HTML format



Single Articles


    October 2021
  1. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    


  2. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    


  3. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    


    September 2021
  4. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed    


    July 2021
  5. GOODWIN PJ
    Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer.
    N Engl J Med. 2021;385:462-463.
    PubMed    


  6. GNANT M, Fitzal F, Rinnerthaler G, Steger GG, et al
    Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
    N Engl J Med. 2021;385:395-405.
    PubMed     Abstract available


  7. BARDIA A, Hurvitz SA, Rugo HS
    Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
    N Engl J Med. 2021;385:e12.
    PubMed    


  8. GANGULY S, Gogia A
    Sacituzumab Govitecan in Metastatic Breast Cancer.
    N Engl J Med. 2021;385:e12.
    PubMed    


    June 2021
  9. TUTT ANJ, Garber JE, Kaufman B, Viale G, et al
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    N Engl J Med. 2021 Jun 3. doi: 10.1056/NEJMoa2105215.
    PubMed     Abstract available


    April 2021
  10. BARDIA A, Hurvitz SA, Tolaney SM, Loirat D, et al
    Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2021;384:1529-1541.
    PubMed     Abstract available


    March 2021
  11. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
    N Engl J Med. 2021;384:1176-1177.
    PubMed    


  12. COPUR MS
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2021;384:1176.
    PubMed    


    January 2021
  13. DORLING L, Carvalho S, Allen J, Gonzalez-Neira A, et al
    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948.
    PubMed     Abstract available


  14. NAROD SA
    Which Genes for Hereditary Breast Cancer?
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMe2035083.
    PubMed    


  15. HU C, Hart SN, Gnanaolivu R, Huang H, et al
    A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.
    PubMed     Abstract available


    December 2020
  16. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2020;383:2557-2570.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: